Schizophrenia likely involves multiple pathophysiological elements, most of which are not affected by current neuroleptic treatments. The goal of this study is to investigate effects of a new drug therapy directed to one of these elements, a recently identified, genetically transmitted deficit in the a7 nicotinic acetylcholine receptor locus. The cx7 nicotinic receptor is a good candidate for the development of new therapeutic strategies for several reasons: (1) this receptor is the only currently identified neurotransmitter receptor for which there is independent biological and genetic evidence of involvement in the pathophysiology of schizophrenia; and (2) the pathophysiological dysfunction is closely associated with disordered attentional function, which has been found to be related to poor psychosocial outcome. The proposed experiments will identify the neurophysiological, neuropsychological, and clinical effects of a7 receptor activation in both schizophrenics and their relatives. Scientific questions about the role of the receptor in the pathophysiology of schizophrenia, as well as the issue of its utility as a therapeutic target, cannot be adequately addressed without the development of strategies for selective activation of the a7 receptor in human subjects. Therefore, included in the experimental plan are Phase 1, proof of principle, tests for a new a7 nicotinic agonist, 3-(2,4 dimethoxybenzylidene) anabaseine (DMXB-A).

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
1R01MH061412-01A1
Application #
6266926
Study Section
Special Emphasis Panel (ZRG1-BDCN-6 (01))
Program Officer
Brady, Linda S
Project Start
2001-02-05
Project End
2005-01-31
Budget Start
2001-02-05
Budget End
2002-01-31
Support Year
1
Fiscal Year
2001
Total Cost
$509,891
Indirect Cost
Name
University of Colorado Denver
Department
Psychiatry
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Smucny, Jason; Rojas, Donald C; Eichman, Lindsay C et al. (2013) Neural effects of auditory distraction on visual attention in schizophrenia. PLoS One 8:e60606
Tregellas, Jason R; Tanabe, Jody; Rojas, Donald C et al. (2011) Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry 69:7-11
Slavov, Svetoslav H; Radzvilovits, Maksim; LeFrancois, Susan et al. (2010) A computational study of the binding of 3-(arylidene) anabaseines to two major brain nicotinic acetylcholine receptors and to the acetylcholine binding protein. Eur J Med Chem 45:2433-46
Tregellas, Jason R; Olincy, Ann; Johnson, Lynn et al. (2010) Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia. Neuropsychopharmacology 35:938-42
Hibbs, Ryan E; Sulzenbacher, Gerlind; Shi, Jianxin et al. (2009) Structural determinants for interaction of partial agonists with acetylcholine binding protein and neuronal alpha7 nicotinic acetylcholine receptor. EMBO J 28:3040-51
Arias, H R; Xing, H; Macdougall, K et al. (2009) Interaction of benzylidene-anabaseine analogues with agonist and allosteric sites on muscle nicotinic acetylcholine receptors. Br J Pharmacol 157:320-30
Freedman, Robert; Olincy, Ann; Buchanan, Robert W et al. (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165:1040-7
Olincy, Ann; Harris, Josette G; Johnson, Lynn L et al. (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63:630-8
Talley, Todd T; Yalda, Samar; Ho, Kwok-Yiu et al. (2006) Spectroscopic analysis of benzylidene anabaseine complexes with acetylcholine binding proteins as models for ligand-nicotinic receptor interactions. Biochemistry 45:8894-902
Harris, Josette G; Kongs, Susan; Allensworth, Diana et al. (2004) Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 29:1378-85

Showing the most recent 10 out of 12 publications